.png){kind=icon}
.png){kind=icon}
Return
Switching from intravenous to subcutaneous tocilizumab for uveitis during the COVID-19 pandemic: a case series
.png){kind=icon}
PRE
AI
DOI：.png)
.png){kind=icon}
Original request for help.png){kind=icon}
Share.png){kind=icon}
Save
Abstract
En
Journal
C
IF:
2.8
Papers:
3.6K
Citations:
2.8K
Organization
No organization information available
Cited Papers